Clinical TrailsAxsome Therapeutics Doses First Patient in Phase 3 FORWARD Trial of AXS-14 ... Axsome Therapeutics Doses First Patient in Phase 3 FORWARD Trial of AXS-14 ... Read Post »
Clinical TrailsJohnson & Johnson Presents New Evidence That CAPLYTA With Antidepressan... Johnson & Johnson Presents New Evidence That CAPLYTA With Antidepressan... Read Post »
Clinical TrailsAbbVie and Genmab Report Phase 3 Results for Epcoritamab in Relapsed DLBCL AbbVie and Genmab Report Phase 3 Results for Epcoritamab in Relapsed DLBCL Read Post »
Clinical TrailsTeva’s AJOVY Demonstrates Strong Efficacy in Reducing Pediatric Migraine ... Teva’s AJOVY Demonstrates Strong Efficacy in Reducing Pediatric Migraine ... Read Post »
Clinical TrailsTanabe Pharma Reports Positive Phase 3 INSPIRE Results for MT-7117 in EPP a... Tanabe Pharma Reports Positive Phase 3 INSPIRE Results for MT-7117 in EPP a... Read Post »
Clinical TrailsPhase 3 MajesTEC-9 Trial Shows TECVAYLI® Monotherapy Improves Survival in ... Phase 3 MajesTEC-9 Trial Shows TECVAYLI® Monotherapy Improves Survival in ... Read Post »
Clinical TrailsBristol Myers Squibb Reports Positive Phase 3 SCOUT-HCM Results for Camzyos... Bristol Myers Squibb Reports Positive Phase 3 SCOUT-HCM Results for Camzyos... Read Post »
Clinical TrailsJohnson & Johnson’s RYBREVANT® Shows Promising Long-Term Results in ... Johnson & Johnson’s RYBREVANT® Shows Promising Long-Term Results in ... Read Post »
Clinical TrailsBepirovirsen Shows Phase III Success in Chronic Hepatitis B, GSK Confirms Bepirovirsen Shows Phase III Success in Chronic Hepatitis B, GSK Confirms Read Post »
Clinical TrailsLilly’s Taltz Plus Zepbound Delivers Superior Outcomes in Phase 3b Psoria... Lilly’s Taltz Plus Zepbound Delivers Superior Outcomes in Phase 3b Psoria... Read Post »
Clinical TrailsJohnson & Johnson Reports Positive Phase 2b JASMINE Trial Results for N... Johnson & Johnson Reports Positive Phase 2b JASMINE Trial Results for N... Read Post »
Clinical TrailsFull Phase 3 TULIP-SC Results Support Self-Administered Saphnelo for Lupus Full Phase 3 TULIP-SC Results Support Self-Administered Saphnelo for Lupus Read Post »
Clinical TrailsDenali’s Tividenofusp Alfa (DNL310) Phase 1/2 Data in Hunter Syndrome wit... Denali’s Tividenofusp Alfa (DNL310) Phase 1/2 Data in Hunter Syndrome wit... Read Post »
Clinical TrailsGalapagos GLPG3667 Meets Primary Endpoint in Dermatomyositis Phase 3-Enabli... Galapagos GLPG3667 Meets Primary Endpoint in Dermatomyositis Phase 3-Enabli... Read Post »
Clinical TrailsTirzepatide Matches Dulaglutide on Major Cardiovascular Outcomes in SURPASS... Tirzepatide Matches Dulaglutide on Major Cardiovascular Outcomes in SURPASS... Read Post »
Clinical TrailsJohnson and Johnson’s JNJ-5939 Falls Short in DUPLEX-AD Phase 2b Trial fo... Johnson and Johnson’s JNJ-5939 Falls Short in DUPLEX-AD Phase 2b Trial fo... Read Post »
Clinical TrailsBiogen Reports Final VALOR Results Showing Earlier QALSODY Treatment May Sl... Biogen Reports Final VALOR Results Showing Earlier QALSODY Treatment May Sl... Read Post »
Clinical TrailsNeurocrine’s Phase 3 KINECT-DCP Trial of Valbenazine Fails to Meet En... Neurocrine’s Phase 3 KINECT-DCP Trial of Valbenazine Fails to Meet En... Read Post »
Clinical TrailsInsmed’s Brensocatib Misses Endpoints in Phase 2b BiRCh Trial for Chronic... Insmed’s Brensocatib Misses Endpoints in Phase 2b BiRCh Trial for Chronic... Read Post »
Clinical TrailsPhase II FALKON Trial Discontinued After Fidrisertib Fails in FOP Phase II FALKON Trial Discontinued After Fidrisertib Fails in FOP Read Post »
Clinical TrailsLilly’s Orforglipron Maintains Weight Loss Post-Wegovy/Zepbound in AT... Lilly’s Orforglipron Maintains Weight Loss Post-Wegovy/Zepbound in AT... Read Post »
Clinical TrailsTakeda’s Zasocitinib Hits All Phase 3 Endpoints in Plaque Psoriasis: ... Takeda’s Zasocitinib Hits All Phase 3 Endpoints in Plaque Psoriasis: ... Read Post »
Clinical TrailsPhase 3 ARTISTRY-2 Data Support Bictegravir–Lenacapavir as a Potential Ne... Phase 3 ARTISTRY-2 Data Support Bictegravir–Lenacapavir as a Potential Ne... Read Post »
Clinical TrailsFDA Awards National Priority Voucher to Teclistamab Plus Daratumumab as Pha... FDA Awards National Priority Voucher to Teclistamab Plus Daratumumab as Pha... Read Post »
Clinical TrailsMazdutide Shows Strong Weight Loss and Metabolic Benefits in Phase 1b Trial... Mazdutide Shows Strong Weight Loss and Metabolic Benefits in Phase 1b Trial... Read Post »
Clinical TrailsAmneal’s Interim Phase 4 ELEVATE-PD Data Shows Extended “Good On”... Amneal’s Interim Phase 4 ELEVATE-PD Data Shows Extended “Good On”... Read Post »
Clinical TrailsEli Lilly’s Triple Agonist Retatrutide Hits Phase 3 Goals in Obesity ... Eli Lilly’s Triple Agonist Retatrutide Hits Phase 3 Goals in Obesity ... Read Post »
Clinical TrailsVertex CASGEVY Breakthrough: First Data in Children 5-11 at ASH 2025, Globa... Vertex CASGEVY Breakthrough: First Data in Children 5-11 at ASH 2025, Globa... Read Post »
Clinical TrailsBreakthrough Rusfertide Phase 3 VERIFY Results: 52-Week Hematocrit Control ... Breakthrough Rusfertide Phase 3 VERIFY Results: 52-Week Hematocrit Control ... Read Post »
Clinical TrailsPfizer’s HYMPAVZI Shows 93% Bleed Reduction in Hemophilia A/B with Inhibi... Pfizer’s HYMPAVZI Shows 93% Bleed Reduction in Hemophilia A/B with Inhibi... Read Post »
Clinical TrailsZorevunersen Four-Year Results Confirm Disease-Modifying Potential in Pedia... Zorevunersen Four-Year Results Confirm Disease-Modifying Potential in Pedia... Read Post »
Clinical TrailsJnJ’s INLEXZO™ Achieves 74% One-Year Disease-Free Survival in BCG-U... JnJ’s INLEXZO™ Achieves 74% One-Year Disease-Free Survival in BCG-U... Read Post »
Clinical TrailsBayer Launches Phase III SUNFLOWER Trial: Mirena 52mg LNG-IUS for Nonatypic... Bayer Launches Phase III SUNFLOWER Trial: Mirena 52mg LNG-IUS for Nonatypic... Read Post »
Clinical TrailsPositive HOPE-3 Phase 3 Results Support Deramiocel as a Potential New Treat... Positive HOPE-3 Phase 3 Results Support Deramiocel as a Potential New Treat... Read Post »
Clinical Trails New Drug ApprovalIonis’ Zilganersen Earns FDA Breakthrough Therapy Designation for Ultra R... Ionis’ Zilganersen Earns FDA Breakthrough Therapy Designation for Ultra R... Read Post »
Clinical TrailsLEQEMBI® (Lecanemab-irmb) CTAD 2025 Data Confirms Aβ Protofibril Reductio... LEQEMBI® (Lecanemab-irmb) CTAD 2025 Data Confirms Aβ Protofibril Reductio... Read Post »
Clinical TrailsEisai Unveils Breakthrough Etalanetug Data at CTAD 2025: Significant Reduct... Eisai Unveils Breakthrough Etalanetug Data at CTAD 2025: Significant Reduct... Read Post »
Clinical TrailsMerck Presents Promising First-in-Human Data for Alzheimer’s Candidates M... Merck Presents Promising First-in-Human Data for Alzheimer’s Candidates M... Read Post »
Clinical TrailsAbbVie’s Phase 3 ECLIPSE Study Shows Atogepant (AQUIPTA®) Superior t... AbbVie’s Phase 3 ECLIPSE Study Shows Atogepant (AQUIPTA®) Superior t... Read Post »
Clinical TrailsOral Mosnodenvir Pill’s Rocky Road: 60% Dengue Success in Phase 2a Tr... Oral Mosnodenvir Pill’s Rocky Road: 60% Dengue Success in Phase 2a Tr... Read Post »
Clinical Trails Health TidingsAlexion Advances ALXN2420 to Phase 2: PeptiDream Unlocks Acromegaly Milesto... Alexion Advances ALXN2420 to Phase 2: PeptiDream Unlocks Acromegaly Milesto... Read Post »
Clinical Trails New Drug ApprovalNovo Nordisk Files FDA sNDA for Wegovy 7.2 mg Higher Dose After 20.7% Weigh... Novo Nordisk Files FDA sNDA for Wegovy 7.2 mg Higher Dose After 20.7% Weigh... Read Post »
Clinical TrailsSarepta Receives FDA Approval to Begin ENDEAVOR Cohort 8 Investigating Enha... Sarepta Receives FDA Approval to Begin ENDEAVOR Cohort 8 Investigating Enha... Read Post »
Clinical TrailsNovo Nordisk’s Amycretin Phase 2 Trial Shows Up to 14.5% Weight Loss and ... Novo Nordisk’s Amycretin Phase 2 Trial Shows Up to 14.5% Weight Loss and ... Read Post »
Clinical TrailsJohnson & Johnson’s Posdinemab Fails to Meet Primary Endpoint in Auτ... Johnson & Johnson’s Posdinemab Fails to Meet Primary Endpoint in Auτ... Read Post »
Clinical TrailsKyowa Kirin Launches Phase 3 AOBA Study of KK8398 (Infigratinib) for Achond... Kyowa Kirin Launches Phase 3 AOBA Study of KK8398 (Infigratinib) for Achond... Read Post »
Clinical TrailsSarepta’s SRP-1003 siRNA Program Hits Key Enrollment Milestone, Triggers ... Sarepta’s SRP-1003 siRNA Program Hits Key Enrollment Milestone, Triggers ... Read Post »
Clinical TrailsNovo Nordisk’s Evoke Phase 3 Trial Fails to Show Semaglutide Benefit in A... Novo Nordisk’s Evoke Phase 3 Trial Fails to Show Semaglutide Benefit in A... Read Post »
Clinical TrailsNew Hope for Stroke Survivors: Bayer’s Asundexian Shows Promise in Reduci... New Hope for Stroke Survivors: Bayer’s Asundexian Shows Promise in Reduci... Read Post »
Clinical TrailsPfizer’s Next-Gen mRNA Flu Shot: A New Standard in Vaccine Innovation Pfizer’s Next-Gen mRNA Flu Shot: A New Standard in Vaccine Innovation Read Post »
